References in periodicals archive ?
Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial.
Economic impact of same-day home discharge after uncomplicated transradial percutaneous coronary intervention and bolus-only abciximab regimen.
Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy.
53, 20) Drugs targeted directly to the GPIIb/IIIa complex include tirofiban, eptibatide and abciximab.
Drugs such as heparin (anti-Xa), abciximab (GP IIb/IIIa antagonists) and bivalirudin, a direct thrombin inhibitor (DTI), are often given as adjuvant therapy in the cardiac catheterization lab.
Likewise, thrombocytopenia induced by a conformational change in GPIIb/IIIa that is recognized by naturally occurring antibodies (such as is case with glycoprotein IIb/IIIa inhibitors abciximab, epitifibatide, and tirofiban) usually leads to the rapid onset of thrombocytopenia on the first exposure to the drug within hours or a few days; thus, such a mechanism probably can also be excluded in our patient (1,5).
Abciximab (Rheopro) has been used to treat thromboembolic complications.
Abciximab improves both epicardial flow and myocardial reperfusion in STelevation myocardial infarction.
Aspirin blocks the production of TXA2, clopidogrel and other P2Y12 inhibitors interfere with the ADP-dependent binding of platelets, and agents such as abciximab block GP Ilb/Illa and platelet aggregation.
Prospective evaluation of early abciximab and primary percutaneous intervention for patients with ST elevation myocardial infarction complicated by cardiogenic shock: results of the REO-SHOCK trial.
Similarly, Qureshi, Suri, Geogiadis, Vazquez, and Janjua (2009) performed a pool of four prospective studies to evaluate the following IA recanalization techniques: (a) IV rtPA and mechanical clot disruption with an Amplatz gooseneck microsnare, (b) IV Abciximab and IA Reteplase, (c) EKOS MicroLys infusion catheter, and (d) IA Reteplase and mechanical clot disruption with an Amplatz gooseneck microsnare, paying close attention to the following three factors: the effect of age of 80 years or older on angiographic recanalization, good outcomes as evidenced by mRS score, and rate of mortality at 1-3 months.